Abstract:Diabetes, whether insulin-dependent or independent is a major cause of endothelial dysfunction and a leading risk factor for cardiovascular disease. While compelling evidence indicates that endothelial dysfunction is a precursor and contributor to cardiovascular disease, the etiology of diabetes-induced endothelial dysfunction remains ill-defined. Recently alteration in endothelial cell bioenergetics has emerged as a new contributor to vascular diseases. However, whether alterations in endothelial glycolysis, the main endothelial cell bioenergetic pathway contributes to endothelial dysfunction is unknown. Herein, we tested the hypothesis that diabetes-associated endothelial dysfunction involved increases in endothelial cells glycolysis and upregulation of its primary regulator, 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase 3 (PFKFB3). Measurement of glycolytic activity via Seahorse analyzer in primary human aortic endothelial cells (HAEC) from control and diabetic patients revealed a significant increase in basal glycolysis in diabetic subjects (p<0.05). We also employed Akita mice, a mouse model of type 1 diabetes. Male Akita mice showed a diabetic phenotype with 3-folds increase in blood glucose. Seahorse analysis in intact aortic explants revealed a 1.7-fold increase in basal glycolysis and a 1.3-fold increase in maximal glycolysis in Akita mice (P<0.05). The increase in glycolysis was endothelial-derived as aortic denudation significantly decreased glycolysis in Akita mice and abolished the difference between groups. No significant difference in mitochondrial function was depicted in the mito-stress test between Akita and WT aortic explants (p>0.05). Additionally, endothelial cells extracted from aortas of Akita mice exhibited a 2-fold increase in PFKFB3 mRNA expression(P<0.05). Interestingly, inhibition of PFKFB3 using 3PO (20μM) restored endothelial function in Akita mice. Similarly, Non-obese diabetic females (NOD), a model for type-1 diabetes, showed 4-fold increases in PFKFB3 mRNA expression in aortic endothelial cells and impaired EDR which was restored with 3PO (p<0.05). To further evaluate the role of PFKFB3 in vascular endothelial function we overexpressed PFKFB3 in WT aortas with adenovirus (Ad-PFKFB3), and reported impaired aorta EDR(P<0.05). Transduction of HAEC with Ad-PFKFB3 showed a significant increase in ROS producing enzyme (NOX1). Also, inhibition of NOX1 using the selective inhibitor GKT771 restored EDR in Akita and Ad-PFKFB3-transduced WT aortas. In Conclusion, our data identified for the first time a role for endothelial glycolysis in the control of vascular relaxation and showed a crucial role of PFKFB3-mediated endothelial glycolysis in vascular endothelial dysfunction associated with Type-1 diabetes in males and females. The underlying mechanism potentially involves NOX1 as a downstream target for PFKFB3. Thus, Inhibitors of PFKFB3 could be a potential therapeutic target for diabetes-induced vascular endothelial dysfunction.

Abstract 719: PFKFB3 Mediated Glycolysis in Vascular Smooth Muscle Cells is Essential for Arterial Neointima Formation

Periostin Mediates Vascular Smooth Muscle Cell Migration Through the Integrins Ανβ3 and Ανβ5 and Focal Adhesion Kinase (FAK) Pathway

Glycolysis and de novo fatty acid synthesis cooperatively regulate pathological vascular smooth muscle cell phenotypic switching and neointimal hyperplasia

Methyltransferase Like 3-Mediated N6-methylatidin Methylation Inhibits Vascular Smooth Muscle Cells Phenotype Switching Via Promoting Phosphatidylinositol 3-Kinase Mrna Decay.

Inhibition of Polycomb Repressor Complex 2 Ameliorates Neointimal Hyperplasia by Suppressing Trimethylation of H3K27 in Vascular Smooth Muscle Cells.

Endothelial PFKFB3 Plays a Critical Role in Angiogenesis.

Inhibition of PFKFB3 Hampers the Progression of Atherosclerosis and Promotes Plaque Stability

PFKFB3 in Smooth Muscle Promotes Vascular Remodeling in Pulmonary Arterial Hypertension

Abstract 3142: Pik3c3 Safeguards Smooth Muscle Identity by Promoting Lysosome-mediated Yap1 Degradation

Abstract 461: Enhanced Glycolysis in Endothelial Cells Protects Against Atherosclerosis

m6A Modification of Profilin-1 in Vascular Smooth Muscle Cells Drives Phenotype Switching and Neointimal Hyperplasia via Activation of the p-ANXA2/STAT3 Pathway

Partial Inhibition of the 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase-3 (PFKFB3) Enzyme in Myeloid Cells Does Not Affect Atherosclerosis

Impairment in Endothelial Bioenergetics Contributes to Diabetes-Induced Vascular Dysfunction.

M 6 A Modification of Profilin-1 in Vascular Smooth Muscle Cells Drives Phenotype Switching and Neointimal Hyperplasia Via Activation of the P-Anxa2/stat3 Pathway

Glycolytic PFKFB3 and Glycogenic UGP2 Axis Regulates Perfusion Recovery in Experimental Hind Limb Ischemia

Abstract 306: Endothelial 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase, Isoform 3 (PFKFB3) Deficiency Inhibits Hypoxia-Induced Pulmonary Hypertension in Mice

MFN2 Prevents Neointimal Hyperplasia in Vein Grafts Via Destabilizing PFK1

Gene-dosage effect of Pfkfb3 on monocyte/macrophage biology in atherosclerosis

Identification of PI3K regulatory subunit p55γ as a novel inhibitor of vascular smooth muscle cell proliferation and neointimal formation.

Suppression of PFKFB3-driven Glycolysis Restrains Endothelial-to-mesenchymal Transition and Fibrotic Response

KLF4-PFKFB3-driven glycolysis is essential for phenotypic switching of vascular smooth muscle cells